News

On November 12, 2026, the FDA approved Biocon’s Pebrilzo™ (pertuzumab-qcay) as a biosimilar of Genentech’s Perjeta® (pertuzumab).  Pebrilzo™ is the second Perjeta® biosimilar approval, following Shanghai Henlius Biotech’s Poherdy® (pertuzumab-dpzb), approved as an interchangeable biosimilar in November 2025 (previously reported FDA Approves First Perjeta® Biosimilar: Shanghai Henlius Biotech / Organon’s Poherdy®).

In October 2026, Genentech and Biocon settled BPCIA litigation No. 2:26-cv-09585 (D.N.J.) allowing the launch of Pebrilzo™ in the third quarter of 2028, or earlier in certain undisclosed circumstances (previously reported Genentech and Biocon Settle Perjeta® BPCIA Litigation).

In January 2026, Genentech and Shanghai Henlius Biotech settled BPCIA litigation No. 2:25-cv-14648 (D.N.J.) related to Poherdy® (previously reported Genentech and Shanghai Henlius Biotech Settle Perjeta® Biosimilar BPCIA Litigation).

There are no other ongoing patent disputes related to Perjeta® biosimilars

Roche reported U.S. sales of approximately $1.62B USD (1.27B CHF) for Perjeta® in 2025.

For more information about these and other biosimilars, please visit BiologicsHQ.

 

_____________________________________________________

The author would like to thank April Breyer Menon for her contributions to this article.


    Methodology

    Information contained in the Venable BiologicsHQ database relates to FDA-approved drug products listed in the CDER Purple Book or on the FDA website (www.fda.gov). Information relating to FDA licensed products, FDA-approved indications, and aBLA and 505(b)(2) applications is obtained from public sources including the U.S. FDA website (www.fda.gov). Information relating to litigations is given only for cases active from January 31, 2010 onward. Information relating to foreign biosimilar / biologics follow-on products approved in Australia, Canada, the E.U., Japan and South Korea is from public sources. Statistics graphics are compiled from information contained in the Venable BiologicsHQ database.

    Disclaimer

    The individuals who maintain this site work for Venable LLP. The information, comments and links posted on this site do not constitute legal advice. No attorney-client relationship has been or will be formed by any communication(s) to, from or with the site and/or the author. For legal advice, contact an attorney at Venable LLP or an attorney actively practicing in your jurisdiction. Do not send any confidential or privileged information to the author; neither Venable LLP nor the author will assume any liability or responsibility for it. If you send any information, documents or materials to the site, you give permission for the author to include them on or in the site. No information, documents or materials you send to the site will be considered confidential or privileged by Venable LLP or its lawyers. Also, no such information, documents or materials will be returned to you. All decisions relating to the content belong to the author.

    Subscribe for Future Updates

      captcha